BPG is committed to discovery and dissemination of knowledge
JOURNAL HOME
Number of total visits
2806210
Number of visits today
302
Number of downloads
2058662
MEMBERSHIP
BPG JOURNALS
Cited by in F6Publishing
For: Xu Y, Shu D, Shen M, Wu Q, Peng Y, Liu L, Tang Z, Gao S, Wang Y, Liu S, Cui D. Development and Validation of a Novel PPAR Signaling Pathway-Related Predictive Model to Predict Prognosis in Breast Cancer. Journal of Immunology Research 2022;2022:1-22. [DOI: 10.1155/2022/9412119] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Wu S, Lv X, Wu J, Wei H, Liu S, Zou C, Song J, Li X, Ai Y. Identification and Validation of a Four-Gene Prognostic Signature Based on PPAR Signaling Pathway for Oral Squamous Cell Carcinoma.. [DOI: 10.21203/rs.3.rs-2560274/v1] [Reference Citation Analysis]
2 Pan Y, Zhang Q, Zhang H, Kong F. Prognostic and immune microenvironment analysis of cuproptosis-related LncRNAs in breast cancer. Funct Integr Genomics 2023;23:38. [PMID: 36640225 DOI: 10.1007/s10142-023-00963-y] [Reference Citation Analysis]
3 Cui Y, Huang T, Zhang Z, Yang Z, Hao F, Yuan T, Zhou Z. The potential effect of BMSCs with miR-27a in improving steroid-induced osteonecrosis of the femoral head. Sci Rep 2022;12:21051. [PMID: 36473889 DOI: 10.1038/s41598-022-25407-8] [Reference Citation Analysis]
4 Xu Y, Shen M, Peng Y, Liu L, Tang L, Yang T, Pu D, Tan W, Zhang W, Liu S, Xu Y. Cell Division Cycle-Associated Protein 3 (CDCA3) Is a Potential Biomarker for Clinical Prognosis and Immunotherapy in Pan-Cancer. BioMed Research International 2022;2022:1-28. [DOI: 10.1155/2022/4632453] [Reference Citation Analysis]
5 Xu Y, Jin Y, Gao S, Wang Y, Qu C, Wu Y, Ding N, Dai Y, Jiang L, Liu S, Pan J. Prognostic Signature and Therapeutic Value Based on Membrane Lipid Biosynthesis-Related Genes in Breast Cancer. Journal of Oncology 2022;2022:1-16. [DOI: 10.1155/2022/7204415] [Reference Citation Analysis]
Write to the Help Desk
© 2004-2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345